The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia.

[1]  M. Brechbiel,et al.  Biodistribution and metabolism of targeted and nontargeted protein-chelate-gadolinium complexes: evidence for gadolinium dissociation in vitro and in vivo. , 1995, Magnetic resonance imaging.

[2]  J. Humm,et al.  A model of cell inactivation by alpha-particle internal emitters. , 1993, Radiation research.

[3]  M. Brechbiel,et al.  Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia , 1992 .

[4]  M. Brechbiel,et al.  Convenient synthesis of bifunctional tetraaza macrocycles. , 1992, Bioconjugate chemistry.

[5]  I. Pastan,et al.  Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. , 1991, Cancer research.

[6]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[7]  H. Sakahara,et al.  Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice. , 1989, Cancer research.

[8]  C. Coleman,et al.  Radioimmunotherapy with alpha-particle-emitting immunoconjugates. , 1988, Science.

[9]  H. Sakahara,et al.  Relationship between in vitro binding activity and in vivo tumor accumulation of radiolabeled monoclonal antibodies. , 1988, Journal of Nuclear Medicine.

[10]  R. Squire,et al.  Specific radioimmunotherapy using 90Y-labeled monoclonal antibody in erythroleukemic mice. , 1987, Cancer research.

[11]  M. Strand,et al.  Stability, targeting, and biodistribution of scandium-46- and gallium-67-labeled monoclonal antibody in erythroleukemic mice. , 1985, Cancer research.

[12]  M. Strand,et al.  Specificity, efficacy, and toxicity of radioimmunotherapy in erythroleukemic mice. , 1984, Cancer research.

[13]  D. Scheinberg,et al.  Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. , 1983, Cancer research.

[14]  H. Aposhian,et al.  DMSA and DMPS--water soluble antidotes for heavy metal poisoning. , 1983, Annual review of pharmacology and toxicology.

[15]  D. Scheinberg,et al.  Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. , 1982, Science.

[16]  D. Scheinberg,et al.  Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. , 1982, Cancer research.

[17]  M. Te,et al.  Protection of mice against lethal effects of sodium arsenite--a quantitative comparison of a number of chelating agents. , 1981 .

[18]  Gregory R. Choppin,et al.  Nuclear Chemistry: Theory and Applications , 1980 .

[19]  P. Hammond.  The effects of chelating agents on the tissue distribution and excretion of lead. , 1971, Toxicology and applied pharmacology.

[20]  F. Rauscher.  A virus-induced disease of mice characterized by erythrocytopoiesis and lymphoid leukemia. , 1962, Journal of the National Cancer Institute.

[21]  A. Gordus,et al.  Momentum Transfer to an Atom in a Molecule: Internal Excitation and Bond Dissociation , 1962 .